Search results for "AGENT"

showing 10 items of 8904 documents

Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner

2004

The serotonin type 3 (5-HT(3)) receptor is the only ligand-gated ion channel receptor for serotonin (5-HT). 5-HT(3) receptors play an important role in modulating the inhibitory action of dopamine in mesocorticolimbic brain regions. Neuroleptic drugs are commonly thought to exert their psychopharmacological action mainly through dopamine and serotonin type 2 (5-HT(2)) receptors. Except for clozapine, a direct pharmacological interaction of neuroleptics with 5-HT(3) receptors has not yet been described. Using the concentration-clamp technique, we investigated the effects of flupentixol, various phenothiazines, haloperidol, clozapine and risperidone on Na(+)-inward currents through 5-HT(3) re…

medicine.medical_specialtyPharmacologyKidney5-HT3 receptorCell LineMembrane PotentialsMiceNeuroblastomaCellular and Molecular NeuroscienceDopamineCell Line TumorInternal medicinemedicineAnimalsHumansCalcium SignalingReceptorMolecular BiologyDose-Response Relationship DrugbiologyBrain NeoplasmsChemistryFlupentixolPsychiatry and Mental healthEndocrinologyDopamine receptorCompetitive antagonistbiology.proteinLigand-gated ion channelCalciumSerotoninReceptors Serotonin 5-HT3Ion Channel GatingAntipsychotic AgentsSignal Transductionmedicine.drugMolecular Psychiatry
researchProduct

The metabolic syndrome in hypertension: European society of hypertension position statement.

2008

The metabolic syndrome considerably increases the risk of cardiovascular and renal events in hypertension. It has been associated with a wide range of classical and new cardiovascular risk factors as well as with early signs of subclinical cardiovascular and renal damage. Obesity and insulin resistance, beside a constellation of independent factors, which include molecules of hepatic, vascular, and immunologic origin with proinflammatory properties, have been implicated in the pathogenesis. The close relationships among the different components of the syndrome and their associated disturbances make it difficult to understand what the underlying causes and consequences are. At each of these …

medicine.medical_specialtyPhysiologySodium Chloride Symporter InhibitorsAdrenergic beta-AntagonistsPhysical exerciseAngiotensin-Converting Enzyme InhibitorsType 2 diabetesBioinformaticsInsulin resistanceWeight lossInternal medicineInternal MedicinemedicineHumansThiazideAntihypertensive AgentsMetabolic Syndromebusiness.industrymedicine.diseaseCalcium Channel BlockersObesityExercise TherapyEndocrinologyBlood pressureHypertensionmedicine.symptomMetabolic syndromeCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor BlockersRisk Reduction Behaviormedicine.drugDiet TherapyJournal of hypertension
researchProduct

Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide™.

2015

OBJECTIVE: Cerebral microvascular impairments occurring in AD may reduce Aβ peptide clearance and impact upon circulatory ultrastructure and function. We hypothesized that microvascular pathologies occur in organs responsible for systemic Aβ peptide clearance in a model of AD and that Liraglutide (Victoza(®)) improves vessel architecture. METHODS: Seven-month-old APP/PS1 and age-matched wild-type mice received once-daily intraperitoneal injections of either Liraglutide or saline (n = 4 per group) for eight weeks. Casts of cerebral, splenic, hepatic, and renal microanatomy were analyzed using SEM. RESULTS: Casts from wild-type mice showed regularly spaced microvasculature with smooth lumenal…

medicine.medical_specialtyPhysiologySpleenMice TransgenicKidneyMicrocirculationAmyloid beta-Protein PrecursorMiceAlzheimer DiseaseGlucagon-Like Peptide 1Physiology (medical)Internal medicinemedicinePresenilin-1AnimalsHumansHypoglycemic AgentsMolecular BiologyKidneybusiness.industryLiraglutideMicrocirculationBrainLiraglutideGlucagon-like peptide-1Extravasationmedicine.anatomical_structureEndocrinologyCerebrovascular CirculationCirculatory systemMicrovesselsSystemic administrationCardiology and Cardiovascular MedicinebusinessSpleenmedicine.drugMicrocirculation (New York, N.Y. : 1994)
researchProduct

Causal linear parametric model for baroreflex gain assessment in patients with recent myocardial infarction

2001

Spectral and cross-spectral analysis of R-R interval and systolic arterial pressure (SAP) spontaneous fluctuations have been proposed for noninvasive evaluation of baroreflex sensitivity (BRS). However, results are not in good agreement with clinical measurements. In this study, a bivariate parametric autoregressive model with exogenous input (ARXAR model), able to divide the R-R variability into SAP-related and -unrelated parts, was used to quantify the gain (αARXAR) of the baroreflex regulatory mechanism. For performance assessing, two traditional noninvasive methods based on frequency domain analysis [spectral, baroreflex gain by autogressive model (αAR); cross-spectral, baroreflex gain…

medicine.medical_specialtyPhysiologySystoleEntropyRR intervalMyocardial InfarctionHemodynamicsBlood PressureBaroreflexAutoregressive modelSpectral analysiElectrocardiographyPhenylephrineHeart RateInternal medicinePhysiology (medical)MedicineHumansVasoconstrictor AgentsIn patientAnalysis of VarianceModels Statisticalbusiness.industryModels CardiovascularBaroreflexMiddle AgedR-R-SAP transfer functionSurgeryBlood pressureBaroreflex sensitivityParametric modelCardiologySystolic arterial pressureRegression AnalysisCardiology and Cardiovascular MedicinebusinessRecent myocardial infarction
researchProduct

Practical solutions to the challenges of uncontrolled hypertension: a white paper.

2008

This white paper is an urgent call to action from aninternational group of physicians. The continued failure tocontrolhypertensiontakesanunacceptabletollon patients,families and society and it must be addressed. Any patientwith blood pressure of 140/90 mmHg or greater can becharacterizedasa ‘challengingpatient’,is atsignificant risk,and requires persistent optimization of therapy until targetblood pressure is achieved. Six key challenges in reachingthis goal blood pressure are described: (1) inadequateprimary prevention; (2) faulty awareness of risk; (3) lack ofsimplicity; (4) therapeutic inertia; (5) insufficient patientempowerment; and (6) unsupportive healthcare systems.This white paper id…

medicine.medical_specialtyPhysiologybusiness.industryCall to actionWhite paperBlood pressureHealth careHypertensionInternal MedicinemedicineHumansCardiology and Cardiovascular MedicineIntensive care medicinebusinessAntihypertensive AgentsNeeds AssessmentJournal of hypertension. Supplement : official journal of the International Society of Hypertension
researchProduct

Renal protection by antihypertensive drugs

1998

During the last few years there has been a renewed interest in blood-pressure (BP)-induced kidney damage, owing to a progressive increase in the incidence and prevalence of hypertension and vascular diseases as a cause of end-stage renal disease (ESRD). The need to prevent ESRD demands continued efforts so as to identify early those people with hypertension who are at risk and to provide them with effective antihypertensive therapy. This review analyses what is needed in terms of surrogate endpoints for monitoring kidney damage and what is known about the impact of antihypertensive treatments in reducing the BP burden on the kidney in non-diabetic subjects. Although glomerular filtration ra…

medicine.medical_specialtyPhysiologymedicine.drug_classRenal functionBlood PressureKidneyurologic and male genital diseasesEssential hypertensionNephropathyRisk FactorsInternal medicineInternal MedicinemedicineAlbuminuriaHumansAntihypertensive drugAntihypertensive AgentsKidneyProteinuriabusiness.industrySurrogate endpointmedicine.diseasefemale genital diseases and pregnancy complicationsEndocrinologymedicine.anatomical_structureHypertensionCardiologyKidney Failure ChronicMicroalbuminuriamedicine.symptomCardiology and Cardiovascular MedicinebusinessJournal of Hypertension
researchProduct

Lack of autoreceptor mediated regulation of the spontaneous dopamine turnover in the isolated neurointermediate lobe of the rat pituitary gland in vi…

1990

Isolated neurointermediate lobes of the rat pituitary gland were incubated in Krebs-HEPES solution and the spontaneous outflow of endogenous dopamine and its metabolites (DOPAC, HVA and MOPET) was determined by HPLC with electrochemical detection. The spontaneous outflow of dopamine metabolites (about 1500 fmol/10 min) largely exceeded that of dopamine (about 60 fmol/10 min). Apomorphine concentration-dependently (IC50, 205 nmol/l) reduced the spontaneous outflow of the dopamine metabolites. The effect of apomorphine developed slowly and was progressive over an observation period of 70 min. After 1 h of exposure to a maximall effective concentration of apomorphine (10 mumol/l), the outflow …

medicine.medical_specialtyPituitary gland3-Methoxy-4-hydroxyphenylethanol34-Dihydroxyphenylacetic acidApomorphineDopamineDopamine AgentsIn Vitro TechniquesBiologyReceptors Dopaminechemistry.chemical_compoundDopamineInternal medicineElectrochemistrymedicineAnimalsChromatography High Pressure LiquidPharmacologyHomovanillic acidHomovanillic AcidRats Inbred StrainsGeneral MedicineRatsApomorphineEndocrinologymedicine.anatomical_structurenervous systemchemistryDopamine receptorPituitary GlandAutoreceptor34-Dihydroxyphenylacetic AcidFemaleSulpiridemedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis.

2017

Objective: Deficiency of acetyl-l-carnitine (ALC) seems to play a role in the risk of developing depression, indicating a dysregulation of fatty acid transport across the inner membrane of mitochondria. However, data about ALC supplementation in humans are limited. We thus conducted a systematic review and meta-analysis investigating the effect of ALC on depressive symptoms across randomized controlled trials (RCTs). Methods: A literature search in major databases, without language restriction, was undertaken from inception until 30 December 2016. Eligible studies were RCTs of ALC alone or in combination with antidepressant medications, with a control group taking placebo/no intervention or…

medicine.medical_specialtyPlacebonot knownlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineMedicineHumansAdverse effectApplied PsychologyDepression (differential diagnoses)Randomized Controlled Trials as Topicbusiness.industryDepressionIncidence (epidemiology)Confidence intervalAntidepressive Agents030227 psychiatryPsychiatry and Mental healthMeta-analysisDietary SupplementsVitamin B ComplexAntidepressantbusinessAcetylcarnitine030217 neurology & neurosurgeryPsychosomatic medicine
researchProduct

Experiences of a poison center with metformin-associated lactic acidosis.

2004

Metformin is widely used in the treatment of type 2 diabetes, though it is recognized to be associated with the risk of lactic acidosis. A case of pronounced lactic acidosis with cardiac arrest (pH 6.60, lactate 17.5 mmol/l, base excess - 30, standard bicarbonate 2.5 mmol/l, core body temperature 27.8 degrees C) is presented in a 61-year-old woman under metformin therapy. The key laboratory abnormalities observed during the intensive care treatment including repeated hemodialysis are described. The patient showed a complete recovery with residually reduced mental capabilities. Furthermore, an explorative data analysis of our poison center database from 1995 until 2003 concerning metformin w…

medicine.medical_specialtyPoison Control Centersendocrine system diseasesEndocrinology Diabetes and MetabolismPoison controlSuicide AttemptedType 2 diabetesGastroenterologyEndocrinologyInternal medicineInternal MedicinemedicineHumansHypoglycemic AgentsAcidosisbusiness.industryMetabolic disordernutritional and metabolic diseasesMetabolic acidosisGeneral MedicineMiddle Agedmedicine.diseaseMetforminSurgeryMetforminDiabetes Mellitus Type 2Lactic acidosisBase excessAcidosis LacticFemalemedicine.symptombusinessmedicine.drugExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents

2021

Thrombosis and neoplasms are strictly linked, and the diagnosis of a malignancy is a relevant risk factor for venous thromboembolism (VTE). In particular, between gammopathies, the VTE risk is known to be increased in both monoclonal gammopathy of uncertain significance and in multiple myeloma, with a 3- and 9-fold increase respectively, when compared to the general population. The risk appears to be further increased in patients treated with immunomodulating drugs, such as thalidomide, especially when in combination with dexamethasone or conventional cytotoxic chemotherapies, and lenalidomide. In 2008 the International Myeloma Working Group put out thrombosis prophylaxis recommendations fo…

medicine.medical_specialtyPopulationAntineoplastic Agents030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineFibrinolytic AgentsRisk FactorsInternal medicinemedicineHumansImmunologic FactorsRisk factoreducationMultiple myelomaLenalidomideeducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryWarfarinAnticoagulantsVenous ThromboembolismGeneral MedicineEvidence-based medicinemedicine.diseaseThrombosisPrevention and controlThalidomideTreatment OutcomeMultiple MyelomabusinessProteasome Inhibitorsmedicine.drugPanminerva Medica
researchProduct